Moreover, breast cancer cells with expression of ESR, PGR, or GPER showed higher levels of TET3 after 4-HT treatment, but in triple-negative cells (MDA-MB-231), TET3 was deceased upon 4-HT supplementation (Figure 3). The gene discussed is TET3; the disease is breast carcinoma.